PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT)

Authors :: Pierre Fustier
Cláudia Moreira
Koji Izutsu
G.S. Nowakowski
Laura Fogliatto
Huilai Zhang
Adriana Scheliga
Myron S. Czuczman
Stacey Kalambakas
Ian W. Flinn
Chengqing Wu
Antonello Pinto
Marek Trneny
Nathan Fowler
Fritz Offner
Francesca Re
John G. Gribben
John P. Leonard
Phillip Scheinberg
Xiaonan Hong
Source :: HemaSphere. 3:571-572
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Hematology
Placebo
Lenalidomide/rituximab
Internal medicine
Relapsed refractory
medicine
Indolent Non-Hodgkin Lymphoma
Rituximab
Augment
business
medicine.drug

Tools